Market Cap (In GBp)
8.25 Million
Revenue (In GBp)
-
Net Income (In GBp)
-2.54 Million
Avg. Volume
198.58 Thousand
- Currency
- GBp
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0-14.0
- PE
- -
- EPS
- -
- Beta Value
- -0.727
- ISIN
- GB00BNXH3K91
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Tiffany Jane Thorn BSc. MSc., M.Sc.
- Employee Count
- -
- Website
- https://www.bivictrix.com
- Ipo Date
- 2021-08-11
- Details
- BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.
More Stocks
-
TCO0Tesco PLC
TCO0
-
PREM
-
WLBMF
-
VIVIDHAVisagar Polytex Limited
VIVIDHA
-
UBSUBS Group AG
UBS
-
BRLAFBritish Land Company Plc
BRLAF
-
LOMLFLion One Metals Limited
LOMLF
-
HECPROJECTHEC Infra Projects Limited
HECPROJECT